Healthcare Industry News: UCB
News Release - August 23, 2006
FDA Approves Keppra(R) as Adjunctive Therapy in the Treatment of Myoclonic Seizures in Patients with Juvenile Myoclonic EpilepsyKeppra(R) now approved to treat a generalized seizure type in adult and adolescent patients
BRUSSELS, Belgium, Aug. 23 (HSMN NewsFeed) -- Today UCB announced that the U.S. Food & Drug Administration (FDA) has approved the use of Keppraź (levetiracetam) as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy (JME). Keppraź is widely prescribed as an add-on therapy in the treatment of partial onset seizures in adults and children four years of age and older with epilepsy. This new indication represents the first U.S. approval for Keppraź for the treatment of a generalized seizure type in epilepsy patients.
Commenting on the new U.S. approval Robert C. Knowlton, Associate Professor of Neurology, UAB Epilepsy Center, Birmingham, Alabama, U.S.A. said, 'Juvenile myoclonic epilepsy is an epilepsy syndrome that requires life-long treatment and it is paramount that therapy is both efficacious and well- tolerated in the long term. The trial supporting this new indication for Keppraź presents the first class 1 evidence on the efficacy and safety of an antiepileptic drug as add-on therapy in controlling myoclonic seizures in patients with juvenile myoclonic epilepsy and provides a welcome new treatment option for U.S. physicians and patients'.
Juvenile myoclonic epilepsy is a common epilepsy syndrome that usually starts between the ages of 12 and 18 and accounts for about 10% of all cases of epilepsy(1). It is characterized by myoclonic jerks that occur in 100% of patients, with many also experiencing generalized tonic-clonic and absence seizures(2,3). Juvenile myoclonic epilepsy is frequently misdiagnosed and this can lead to inappropriate treatment choices.(1)
Key Clinical Trial Results
This clinical trial supporting this new indication for Keppraź provides the first and only phase III, double-blind, randomized, placebo-controlled evidence on the safety and efficacy of an antiepileptic drug as add-on therapy in patients with juvenile myoclonic epilepsy experiencing myoclonic seizures. Patients in this study included those with juvenile myoclonic epilepsy, juvenile absence epilepsy or with generalized tonic-clonic seizures on awakening. The majority were patients with juvenile myoclonic epilepsy.
Seizure frequency: The responder rate defined as greater than or equal to 50% reduction in myoclonic seizure days during the treatment period versus baseline was 60.4% in the Keppraź group (n=54), compared with 23.7% in the placebo group (n=59) (p=0.0001)(4)
Seizure freedom: 15.1 % of Keppraź patients achieved freedom from myoclonic seizures during the treatment period compared with 3.4 % of placebo patients(5).
Adverse events: The most common adverse events were somnolence (12% in the Keppraź group versus 2% in the placebo group), neck pain (8% in the Keppraź group versus 2% in the placebo group), and pharyngitis (7% in the Keppraź group versus 0% in the placebo group).(4)
About Keppraź in the USA(4)
Keppraź is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy and as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. Keppraź is associated with the occurrence of central nervous system adverse events including somnolence and fatigue and behavioral abnormalities, as well as hematological abnormalities. In adults experiencing partial onset seizures, Keppraź is also associated with coordination difficulties. In pediatric patients 4-16 years of age experiencing partial onset seizures, the most common adverse events associated with Keppraź in combination with other antiepileptic drugs were somnolence, accidental injury, hostility, nervousness and asthenia. In adults experiencing partial onset seizures, the most common adverse events associated with Keppraź in combination with other AEDs were somnolence, asthenia, infection and dizziness. In adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy, the most common adverse events associated with Keppraź in combination with other antiepileptic drugs were somnolence, neck pain and pharyngitis. Keppraź is also available as an intravenous formulation for the adjunctive treatment of partial-onset seizures in adults with epilepsy. Keppraź injection is an alternative for patients when oral administration is temporarily not feasible. The adverse events that may result from Keppraź injection use for partial onset seizures include all those associated with Keppraź tablets and oral solution. For the U.S., prescribing information is available at www.keppra.com.
Please consult local prescribing information on Keppraź in Europe.
UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is listed on the Euronext Brussels Exchange.
(1) Renganathan R, Delanty N. Juvenile myoclonic epilepsy: under- appreciated and under-diagnosed. Postgraduate Med J 2003; 79: 78-80.
(2) Duron RM, Medina MT, Martinez-Juarez IE, et al. Seizures of idiopathic generalized epilepsies. Epilepsia 2005;46 (supplement 9): 34-47.
(3) Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389-399, 1989. (Table 5, Table 6 and Glossary).
(4) U.S. Keppraź Prescribing Information (www.Keppra.com)
(5) UCB Data on File
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsEVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
UCB announces NAYZILAM(R) (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.